Skip to main
CLOV

CLOV Stock Forecast & Price Target

CLOV Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Clover Health Investments is a healthcare technology company with a unique software platform, Clover Assistant, that empowers physicians to proactively manage chronic diseases and improve health outcomes while lowering medical costs. The company boasts strong retention rates in geographies where its software is adopted, indicating future financial performance. With a growing membership base and a strong focus on markets with solid density and high adoption of its technology, Clover is well-positioned for continued profitability. However, there are potential headwinds in 2027, such as a potential downgrade from a 4-star to a 3.5-star plan and flat rates from CMS, which could impact the company's profitability. Analysts believe that Clover's unique care model and strong use of technology will help manage medical cost trends and drive unit economics for the company in the future.

Bears say

Clover Health Investments is a healthcare technology company that operates in the insurance segment, providing PPO and HMO plans to Medicare Advantage members. However, several potential headwinds, including a shift from being paid as a 3.5 to a 4-star plan and a flat advance rate for 2027, could impact the company's profitability and growth. Furthermore, there are questions surrounding the company's ability to absorb a large new member cohort and retain current members. Overall, the outlook for Clover Health Investments is negative due to these concerns and potential risks to profitability and growth.

CLOV has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clover Health Investments and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clover Health Investments (CLOV) Forecast

Analysts have given CLOV a Buy based on their latest research and market trends.

According to 3 analysts, CLOV has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clover Health Investments (CLOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.